On the basis of the results of the EMILIA trial [18], trastuzumab emtansine (T-DM1) was approved by the U.S. Food and Drug Administration (FDA) in February 2013 for HER2-positive metastatic BC. This evidence concerns the gene ERBB2 and breast cancer.